Related Experiment Video
Updated: Jun 10, 2026
Introduction of Intracapsular Rotary-cut Procedures (IRCP): A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
Published on: January 17, 2019
Efficacy and Safety of Vilaprisan in the Treatment of Uterine Fibroids: Data from ASTEROID 5, a Phase 3 Multicenter
K Gemzell-Danielsson1,2, C-H Cho3, P Vadász4
1Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden.
Abstract:
Background/Objectives: Vilaprisan and ulipristal acetate (UPA) have demonstrated efficacy in treating uterine fibroids (UFs). However, a direct comparison of vilaprisan and UPA has been restricted, to date, to a small phase 2 study. Here, we compare the efficacy of vilaprisan and UPA in reducing heavy menstrual bleeding and inducing amenorrhea in women with symptomatic UFs. Methods: ASTEROID 5 (NCT03240523) was planned as a randomized, active-controlled, multicenter phase 3 study comparing three vilaprisan 2 mg/day regimens against the approved regimen of UPA 5 mg/day for the treatment of symptomatic UFs. Participants were initially randomized 1:1:1:1 to one of four treatment arms: VPR-3/1 (vilaprisan for a 3-month treatment period [TP] followed by one menstrual bleeding episode); VPR-6/2 (vilaprisan for a 6-month TP followed by two menstrual bleeding episodes); VPR-3/2 (vilaprisan plus matching UPA placebo for a 3-month TP followed by two menstrual bleeding episodes); and UPA-3/2 (UPA plus matching vilaprisan placebo for a 3-month TP followed by two menstrual bleeding episodes). Results: Treatment was received as planned by 271 (95.4%), 266 (94.0%), 90 (90.0%) and 89 (89.9%) women in the VPR-3/1, VPR-6/2, VPR-3/2, and UPA-3/2 groups, respectively; 109 women in the VPR-3/1 (n = 44, 15.5%) and VPR-6/2 (n = 65, 23.0%) groups and none in the VPR-3/2 and UPA-3/2 groups completed treatment. Vilaprisan (total VPR group) demonstrated non-inferiority but not superiority versus UPA in inducing amenorrhea (82.9% [520/627] vs. 74.2% [66/89]; difference: 8.8% [95% confidence interval: -0.78, 18.34]; p = 0.0553), whereas vilaprisan (VPR-3/1 arm) showed superiority versus UPA in reducing total menstrual blood loss (least squares mean total MBL: 44.2 mL vs. 80.3 mL; difference: -36.1 mL; p = 0.0010). Conclusions: Vilaprisan (VPR-3/1 regimen) was superior to UPA in reducing total MBL, and it was non-inferior (total VPR group) to UPA in inducing amenorrhea.
